What type of study is this?

This is a Human Clinical Trial study (also classified as: Validation Study).

December 8, 2025BloodOpen Access

Validation of the international working group (IWG) 2023 criteria for clinical benefit in higher risk Myelodysplastic Syndromes (HR-MDS) using a large, international, randomized Phase 3 clinical trial dataset

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial demonstrated improved overall survival with cCR per IWG 2023 criteria in patients with HR-MDS treated with azacitidine.

Achieving a complete composite response per IWG 2023 response criteria significantly improves overall survival.
Patients treated with azacitidine monotherapy in a large clinical trial showed a median overall survival of 18 months.
Landmark analysis indicated patients achieving cCR+PR had an increased overall survival compared to those without it.
The study supports the importance of including composite response criteria in clinical trial assessments for HR-MDS.

Murdock et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark